InMed Pharmaceuticals Appoints Michael Woudenberg as Vice President, Chemistry, Manufacturing, and Controls

This information was provided by prnewswire

Send your Press Release here.


VANCOUVER, Nov. 5, 2018 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, is pleased to announce the appointment of Michael Woudenberg, P.Eng. as Vice President, Chemistry, Manufacturing, and Controls (CMC).

Mr. Woudenberg joins InMed with over twenty years of leadership experience in process engineering, development and commercialization of pharmaceutical products.  Prior to joining InMed, Mr. Woudenberg served as Managing Director at Phyton Biotech, where he was responsible for the operations and manufacturing of active pharmaceutical ingredients (API) from plant cell fermentation, including contract development and manufacturing services to global pharmaceutical companies.  Prior to Phyton Biotech, Mr. Woudenberg held senior CMC-related positions at Arbutus Biopharma and Cardiome Pharmaceuticals.  Mr. Woudenberg earned his degrees in chemistry and chemical engineering from the University of Western Ontario.

Eric A. Adams, InMed’s President and CEO, commented, “During the next year, InMed will be making an important transition from a pre-clinical stage company to a clinical stage company; this is seminal milestone for us.  To successfully make this transition, it’s imperative that we build our internal expertise in CMC for both our clinical stage products, as well as to support the evolution of our proprietary biosynthesis manufacturing technology towards commercial scale-up.”  Mr. Adams continued, “Michael’s extensive experience, professional accomplishments and leadership skills will be a significant contribution towards the Company’s success. We are fortunate and excited to bring Michael on board.”

“It’s clear to me that InMed’s biosynthesis technology is cutting-edge, and has the potential to lead the industry in this emerging field of alternative manufacturing of pharmaceutical-grade cannabinoids,” commented Mr. Woudenberg.  “I’m excited to join InMed’s experienced leadership team and look forward to working with my new colleagues to help accomplish InMed’s mission.”

Emerald contributor since March 2012


Your email address will not be published.